

**DEPARTMENT OF JUSTICE****Antitrust Division****Notice Pursuant to the National Cooperative Research and Production Act of 1993—Cooperative Research Group Corrosion Under Insulation—Phase 2 (CUI—Phase 2)**

Notice is hereby given that, on January 6, 2025, pursuant to section 6(a) of the National Cooperative Research and Production Act of 1993, 15 U.S.C. 4301 *et seq.* (“the Act”), Cooperative Research Group Corrosion Under Insulation—Phase 2 (CUI—Phase 2) has filed written notifications simultaneously with the Attorney General and the Federal Trade Commission disclosing (1) the identities of the parties to the venture and (2) the nature and objectives of the venture. The notifications were filed for the purpose of invoking the Act’s provisions limiting the recovery of antitrust plaintiffs to actual damages under specified circumstances.

Pursuant to section 6(b) of the Act, the identities of the parties to the venture are: Conoco Phillips Company, Houston, TX; Nanotech Inc., Houston, TX; Armancell Engineered Systems Ltd., London, UNITED KINGDOM; The Sherwin Williams Company, Cleveland, OH; PPG Industries, Incorporated, Pittsburgh, PA; International Paint LLC, Houston, TX; Superior Products International II, Inc., Shawnee, KS; Promat Incorporated, Maryville, TN; Jotun A/S, Sandefjord, KINGDOM OF NORWAY; Hempel A/S, Lyngby, KINGDOM OF DENMARK; BP America Production Company, Houston, TX; Air Products and Chemicals, Inc., Allentown, PA; Aspen Aerogels, Inc., Marlborough, MA; Exxonmobil Technology and Engineering, Spring, TX; and Equinor Energy AS, Stavanger, KINGDOM OF NORWAY. The general area of CUI—Phase 2’s planned activities are to test the performance of protective coating and insulation products including insulative coatings using the TM21442 test method and a variant of that approach. In addition to the laboratory and field activities, Phase 2 CUI JIP will be used to test, in laboratory setups, promising CUI sensing technologies suitable for CUI monitoring. These preliminary tests will investigate and compare the performance of a range of CUI sensors using the test methodologies proposed above. The CUI Phase 2 JIP shall focus on four primary technical tasks as follows: performance testing of CUI Protective Coating/Insulation Systems;

performance evaluation of CUI Insulative Coatings; performance evaluation of CUI Insulative Coatings; and preliminary evaluation of CUI Sensors.

**Suzanne Morris,**

*Deputy Director Civil Enforcement Operations, Antitrust Division.*

[FR Doc. 2025–10815 Filed 6–12–25; 8:45 am]

**BILLING CODE P**

**DEPARTMENT OF JUSTICE****Antitrust Division****Notice Pursuant to the National Cooperative Research and Production Act of 1993—Rapid Response Partnership Vehicle**

Notice is hereby given that, on April 8, 2025, pursuant to section 6(a) of the National Cooperative Research and Production Act of 1993, 15 U.S.C. 4301 *et seq.* (“the Act”), Rapid Response Partnership Vehicle (“RRPV”) has filed written notifications simultaneously with the Attorney General and the Federal Trade Commission disclosing changes in its membership. The notifications were filed for the purpose of extending the Act’s provisions limiting the recovery of antitrust plaintiffs to actual damages under specified circumstances.

Specifically, Fisher BioServices, Inc., Rockville, MD; Landmark Vaccines, Ltd., Loughborough, UNITED KINGDOM; Rx Bandz, Locust Valley, NY; Zeteo Tech, Inc., Sykesville, MD; BioNet-Asia Co., Ltd, Bangkok, KINGDOM OF THAILAND; EmitBio, Inc., Morrisville, NC; Matisse Pharmaceuticals, B.V., Geleen, KINGDOM OF THE NETHERLANDS; National Institute for Pharmaceutical Technology and Education, Inc., Minneapolis, MN; ProtonDx, Ltd., London, UNITED KINGDOM; BioVaxys Technology Corp., Etobicoke, CANADA; Enplas, Santa Clara, CA; RHEAVITA BV, Ghent, KINGDOM OF BELGIUM; Celltheon, Union City, CA; Chromatan, Inc., Lower Gwynedd, PA; Cyrus Biotechnology, Seattle, WA; Eradivir, Inc., West Lafayette, IN; InDevR, Inc., Boulder, CO; Kudo Biotechnology, Inc., Needham, MA; Panoplia Laboratories, Inc., Cambridge, MA; The Regents of the University of California on behalf of its Los Angeles campus, Los Angeles, CA; Meridian Medical Technologies LLC, St. Louis, MO; Sarfez Pharmaceuticals, Inc., Vienna, VA; Tiba Biotech LLC, Cambridge, MA; Ecolab, Inc., Philadelphia, PA; Unicorn Biotechnologies, Inc., Newark, NJ;

Zipcode Bio, Weston, MA; Acclinate, Inc., Birmingham, AL; Klim-Loc Medical, Inc., Carbondale, CO; Primary Diagnostics, Inc. dba Primary.Health, San Francisco, CA; Epitogenesis, Inc., Virginia Beach, VA; Microbio, Ltd., Brisbane, COMMONWEALTH OF AUSTRALIA; Aldevron LLC, Fargo, ND; BC3 Technologies, Inc., Baltimore, MD; Genvax, Ames, IA; Maxim Biomedical, Inc., Rockville, MD; Piezo Therapeutics, Inc., Atlanta, GA; Virtu, Inc., Leesburg, VA; Digital Infuzion LLC, Rockville, MD; Neolixir, Ltd., Perth, AUSTRALIA; XCMR, Inc., Narberth, PA; GenevationUS LLP, Sacramento, CA; Respana Therapeutics, Inc., Philadelphia, PA; University of Louisiana at Lafayette, Lafayette, LA; EriVan, Alachua, FL; President and Fellows of Harvard College, Cambridge, MA; MedinCell, Inc., Jacou, FRENCH REPUBLIC; Ambient Biosciences, Ann Arbor, MI; Antirna, Inc., Burlington, MA; Avid Bioservices, Inc., Tustin, CA; CMC Pharmaceuticals, Inc., Solon, OH; FluGen, Inc., Madison, WI; Foundry, Boston, MA; Nutrivert, Inc., Atlanta, GA; The United States Pharmacopeial Convention, Inc., Rockville, MD; Particella, Inc., San Francisco, CA; Ampulis, Inc., Berwyn, PA; Rozum Consulting, Newtown, PA; Halomine, Inc. dba AvantGuard, Ithaca, NY; Luminary Labs LLC, New York, NY; Pluri Biotech, Ltd., Haifa, STATE OF ISRAEL; Public Health Vaccines LLC, Cambridge, MA; B&S Research, Inc., Embarrass, MN; and General Therapeutics, Inc., Gaithersburg, MD have been added as parties to this venture.

Also, TFF Pharmaceuticals, Inc., Fort Worth, TX; Spring Discovery, Inc., San Carlos, CA; Cue Health, Inc., San Diego, CA; and Deimos Biosciences, San Francisco, CA have withdrawn as parties to this venture.

No other changes have been made in either the membership or planned activity of the group research project. Membership in this group research project remains open, and RRPV intends to file additional written notifications disclosing all changes in membership.

On January 5, 2024, RRPV filed its original notification pursuant to section 6(a) of the Act. The Department of Justice published a notice in the **Federal Register** pursuant to section 6(b) of the Act on April 16, 2024 (89 FR 26928).

The last notification was filed with the Department on January 16, 2025. The Department of Justice published a notice in the **Federal Register** pursuant